Two months after gaining US approval, ViiV Healthcare has received an EU marketing authorization for its new once-daily single-pill two-drug HIV combination, Dovato (dolutegravir 50mg/lamivudine 300mg) tablets, a potential blockbuster product which could challenge market leaders, including Gilead Sciences Inc.'s Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide fumarate 25mg) tablets, in the sector.
ViiV highlighted the potential role of Dovato as first-line therapy for treatment-naive patients in its approval announcement on 3 July:...







